molecular
biolog
significantli
improv
diagnosi
field
clinic
virolog
viru
discoveri
rapid
implement
diagnost
test
newli
discov
virus
strongli
benefici
develop
molecular
techniqu
viral
load
antivir
resist
subtyp
assay
part
biolog
monitor
patient
chronic
infect
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
cmv
import
add
panel
assay
virus
herpesvirida
famili
qualit
assay
detect
bloodborn
virus
increas
safeti
blood
donat
organ
transplant
screen
bloodborn
virus
parvoviru
hav
multiplex
detect
test
autom
improv
practic
reduc
cost
next
step
major
evolut
near
futur
gener
nat
diagnosi
viral
etiolog
patient
mostli
respiratori
cn
gastrointestin
diseas
major
technic
improv
made
avoid
obstacl
still
limit
gener
ie
genet
variabl
virus
multiplex
detect
contamin
risk
commerci
offer
alreadi
exist
menu
must
extend
limit
valid
document
work
associ
homebrew
assay
realtim
amplif
allow
develop
new
nat
platform
autom
integr
step
reaction
still
requir
reduc
handsontim
timetoresult
cost
increas
throughput
molecular
biolog
revolution
domain
virus
diagnosi
includ
rapid
identif
emerg
reemerg
virus
viral
safeti
blood
product
organ
transplant
viral
diseas
manag
one
major
drive
forc
introduct
molecular
techniqu
virolog
absenc
easi
perform
multipl
techniqu
similar
develop
bacteriolog
strike
illustr
power
molecular
techniqu
concern
blood
transmit
viruseshuman
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
spectacular
progress
detect
treatment
viral
diseas
made
follow
introduct
qualit
quantit
nucleic
acid
test
nat
recent
discoveri
new
human
coronaviru
respons
sever
acut
respiratori
syndrom
sar
epidem
anoth
exampl
obviou
nat
encourag
develop
antivir
drug
compar
antibiot
delay
partli
perform
effici
assess
techniqu
lack
last
year
mani
new
human
pathogen
discov
among
eight
virus
variou
pathogen
molecular
techniqu
play
central
role
discoveri
tabl
construct
cdna
librari
clone
techniqu
use
identifi
hcv
hepat
e
viru
represent
differ
analysi
rda
success
identifi
human
herp
viru
hepat
virus
gbvc
ttv
rda
allow
detect
viral
sequenc
compar
whole
nucleic
acid
sequenc
cell
human
anim
infect
reversetrancript
polymeras
chain
reaction
rtpcr
random
degener
primer
use
identifi
human
metapneumoviru
hmpv
viru
sen
coronaviru
associ
sar
sarscov
molecular
techniqu
alon
allow
character
import
human
pathogen
like
respons
kaposi
sarcoma
hcv
induc
acut
chronic
hepat
cirrhosi
hepatocarcinoma
howev
virus
detect
similar
way
still
wait
demonstr
clinic
import
illustr
need
verifi
koch
postul
import
keep
laboratori
compet
classic
virologytissu
cultur
electron
microscopi
anim
experimentswhich
play
major
role
viru
discoveri
togeth
epidemiolog
studi
larg
epidemiolog
studi
also
requir
assess
clinic
interest
new
pathogen
molecular
diagnost
rapidli
implement
clinic
virolog
laboratori
follow
discoveri
hmpv
van
den
hoogen
et
al
peiri
et
al
boivin
et
al
sarscov
ksiazek
et
al
drosten
et
al
anderson
prospect
studi
preval
hmpv
could
initi
earli
winter
although
viru
discov
week
lag
sequenc
sarscov
avail
first
commerci
nat
nat
use
exclud
blood
donat
patient
infect
virus
allain
hcv
hiv
test
implement
part
routin
screen
blood
bank
european
countri
respect
franc
two
commerci
offer
procleix
genprob
inc
usa
nuclisen
extractor
biomerieux
franc
associ
coba
ampliscreen
roch
diagnost
switzerland
use
screen
donat
hiv
hcv
infect
allow
reduct
residu
risk
million
hiv
million
hcv
assal
et
al
howev
room
improv
contamin
blood
unit
still
miss
due
lack
sensit
induc
pool
strategi
cost
constraint
must
also
consid
improv
consid
cost
effect
hiv
hcv
nat
addit
serolog
test
alreadi
low
usa
calcul
cost
save
life
million
us
per
year
jackson
et
al
hepat
b
viru
screen
use
molecular
biolog
also
includ
even
recent
antigen
assay
hbsag
assay
miss
infect
blood
unit
exampl
singlesampl
hbv
test
would
allow
detect
addit
contamin
unit
among
unit
test
biswa
et
al
monoval
trival
assay
hiv
hbv
hcv
propos
roch
diagnost
ampli
nat
genprob
procleix
ultrio
blood
unit
pool
provid
suffici
sensit
procleix
ultrio
detect
singl
seroconvers
day
earlier
abbott
prismhbsag
day
pool
day
pool
altern
ultracentrifug
step
could
introduc
follow
pool
obtain
higher
sensit
compar
current
antigen
assay
roth
et
al
screen
westnil
viru
contamin
implement
us
blood
bank
late
june
midseptemb
approxim
million
donat
screen
twelv
hundr
eightyf
initi
reactiv
wnv
use
nucleic
acidamplif
test
total
donat
consid
presumpt
virem
donat
ie
donat
repeatedli
reactiv
primari
andor
altern
nat
assay
primari
nat
assay
high
signal
cdc
virus
parvoviru
hepat
viru
also
transmit
blood
donat
may
part
screen
near
futur
howev
nat
may
alway
best
diagnosi
approach
antigen
test
antibodi
test
may
effici
less
expens
altern
autom
integr
nat
necessari
reduc
cost
quarantin
delay
blood
unit
suppli
respect
recent
approv
us
food
drug
administr
fda
tigri
molecular
diagnost
system
genprob
san
diego
usa
major
breakthrough
design
process
sampl
h
integr
timetoresult
also
import
paramet
consid
insur
viral
safeti
transplant
organ
especi
lung
heart
liver
import
determin
statu
transplant
regard
infect
hiv
hbv
hcv
virus
herpesvirida
famili
nat
significantli
improv
identif
virus
etiolog
agent
human
diseas
affect
variou
organ
especi
respiratori
gastroenter
tract
central
nervou
system
cn
consequ
rapid
antivir
treatment
initi
consider
reduc
morbid
mortal
exampl
case
herp
enceph
increas
number
avail
antivir
drug
even
accentu
need
posit
viral
identif
similarli
unnecessari
antibiot
treatment
avoid
reduc
hospitalis
durat
shorten
treatment
chronic
viral
diseas
effici
monitor
viral
load
assay
howev
still
obstacl
prevent
wider
dissemin
molecular
assay
extrem
genet
variabl
virus
especi
rna
virus
rnapolymeras
proofread
activ
often
make
diagnosi
difficult
strike
exampl
found
noroviru
famili
contain
virus
respons
vast
major
gastrointestin
epidem
adult
hiv
diagnosi
also
quit
difficult
achiev
due
high
genet
variabl
gardner
et
al
deduc
sequenc
align
realtim
taqman
assay
contain
less
nine
primer
probe
set
detect
sensit
hiv
strain
geograph
repres
panel
reduc
impact
variabl
amplif
detect
effici
one
use
primer
probe
omethyl
base
degener
base
univers
base
inosin
nebularin
touchdown
pcr
protocol
anneal
temperatur
slightli
decreas
success
amplif
cycl
bracket
melt
temperatur
tm
reaction
provid
sensit
even
primer
mismatch
target
sequenc
diverg
speci
viral
famili
final
degener
primer
probe
mixtur
base
found
sequenc
databas
among
variou
speci
may
use
detect
speci
viral
famili
often
desir
provid
capabl
panel
detect
ie
detect
sever
virus
respons
diseas
exampl
coyl
et
al
describ
winter
meet
european
societi
clinic
virolog
copenhagen
januari
molecular
viral
respiratori
strip
detect
common
respiratori
virus
whenev
possibl
consensu
primer
abl
detect
virus
famili
genu
must
use
sever
exampl
consensu
primer
enteroviru
kammer
et
al
flaviviru
scaramozzino
et
al
herpesvirida
tenorio
et
al
howev
abil
amplifi
virus
effici
must
care
evalu
approach
possibl
two
differ
possibl
exist
panel
detect
multiplex
detect
singl
tube
parallel
detect
individu
tube
mix
primer
singl
amplif
tube
achiev
multiplex
detect
virus
usual
result
decreas
sensit
assay
compar
singl
test
exampl
observ
use
dnamicroarray
assay
see
analyt
sensit
multiplex
rtpcr
detect
six
virus
ie
influenza
influenza
b
rsv
ab
parainfluenza
reduc
factor
log
compar
singl
detect
depend
viru
nevertheless
multiplex
assay
abl
identifi
correctli
infect
respiratori
specimen
one
rsv
b
infect
misidentifi
rsv
unpublish
data
format
primer
dimer
gener
consid
major
caus
sensit
loss
care
optimis
paramet
amplif
includ
primer
enzym
nucleotid
salt
concentr
well
protocol
condit
requir
obtain
expect
perform
realtim
assay
see
monitor
signal
apparit
amplif
step
also
limit
capac
realiz
multiplex
detect
number
avail
wavelength
exist
equip
current
allow
detect
three
virus
instead
mix
sever
pair
primer
singl
tube
nucleic
acid
purifi
origin
clinic
specimen
distribut
sever
tube
independ
amplif
detect
major
drawback
approach
reduct
sensit
lower
amount
nucleic
acid
avail
individu
amplif
higher
handson
time
requir
manipul
differ
tube
difficulti
autom
distribut
small
volum
purifi
nucleic
acid
without
introduc
crosscontamin
higher
cost
due
need
enzym
tube
intern
control
ic
import
compon
monitor
step
assay
extract
nucleic
acid
detect
inhibitor
amplif
reaction
frequent
specimen
type
also
impact
amplif
presenc
ic
strong
valid
case
neg
result
niester
describ
origin
approach
intern
control
nat
use
viral
univers
control
ad
specimen
amplifi
specif
primer
prefer
multiplex
format
primer
viru
detect
seal
herp
viru
phocin
distemp
viru
use
control
nat
dna
rna
virus
respect
cours
anim
virus
infect
human
requir
strategi
ic
involv
synthet
materi
ie
plasmid
transcript
contain
sequenc
abl
bind
test
primer
specif
probe
clinic
virolog
laboratori
high
expect
term
autom
integr
molecular
assay
major
bottleneck
workflow
laboratori
level
sampl
prepar
tabl
show
autom
system
nucleic
acid
purif
current
commercialis
use
nucleic
acid
bind
properti
silica
boom
et
al
mani
sampl
handl
singl
run
biorobot
qiagen
gmbh
germani
timetoresult
import
handsontim
tend
decreas
recent
equip
requir
longer
min
technician
time
sampl
new
label
technolog
need
solidphas
separ
allow
develop
realtim
molecular
assay
detect
amplicon
done
soon
appear
amplif
simpl
realtim
detect
chemistri
use
sybr
green
dye
specif
bind
doublestrand
dna
gener
pcr
sever
probe
technolog
fig
also
design
realtim
assay
like
taqman
fig
molecular
beacon
fig
quencher
molecul
remov
vicin
fluoresc
marker
upon
bind
rna
dna
gener
amplif
cycl
fret
technolog
fig
two
probe
one
fluoresc
donor
one
fluoresc
acceptor
molecul
design
bind
adjac
sequenc
amplifi
materi
gener
signal
mackay
et
al
realtim
techniqu
design
pcr
nasba
amplif
sever
advantag
facilit
autom
reduc
timetoresult
min
handsontim
perform
close
devic
need
open
transfer
amplifi
materi
endpoint
detect
thu
reduc
risk
laboratori
sampl
crosscontamin
use
realtim
platform
make
gener
organis
molecular
biolog
laboratori
easier
reduc
constraint
activ
segreg
differ
room
control
contamin
tabl
show
exist
realtim
autom
next
gener
nat
platform
integr
sampl
prepar
amplif
detect
singl
test
devic
genexpert
cepheid
usa
first
fulli
integr
system
allow
detect
bacillu
anthraci
group
b
streptococcu
approxim
min
directli
clinic
specimen
sever
viral
assay
base
realtim
nasba
platform
soon
avail
biomerieux
sever
ivd
compani
offer
commerci
nat
diagnosi
viral
diseas
besid
technic
difficulti
anoth
obstacl
develop
molecular
assay
import
resourc
need
optimis
produc
valid
homebrew
assay
build
document
requir
qualif
techniqu
laboratori
new
european
commun
regul
even
increas
need
role
vitro
diagnost
ivd
compani
provid
reagent
result
care
optimis
produc
accord
high
qualiti
manufactur
procedur
clinic
regulatori
affair
depart
conduct
valid
studi
assembl
document
requir
get
approv
reagent
howev
even
ivd
compani
concept
valid
process
timeconsum
timetomarket
may
long
especi
problem
diagnost
tool
urgent
need
case
emerg
new
viru
one
possibl
reduc
timetomarket
releas
research
use
ruo
assay
assay
ce
analyt
approv
europ
statu
analyt
specif
reagent
asr
usa
case
commerci
product
excel
analyt
sensit
manufactur
accord
qualiti
standard
ivd
industri
use
clinic
virolog
laboratori
respons
valid
use
diagnost
tool
obtain
author
use
infect
hiv
hepat
b
c
virus
usual
well
diagnos
use
serolog
diagnosi
earli
primoinfect
may
benefit
nat
platform
like
amplicor
amplicor
roch
diagnost
easyq
biomerieux
usual
use
viral
load
measur
therapi
see
also
suitabl
earli
detect
hiv
hcv
infect
mani
infect
especi
acut
infect
igm
appear
sever
day
onset
symptom
effici
diagnos
use
serolog
assay
forti
sixti
percent
commun
acquir
pneumonia
requir
hospitalis
known
aetiolog
despit
intens
investig
percentag
even
higher
less
sever
lower
respiratori
tract
infect
lrti
consid
l
kaiser
person
commun
recent
studi
henrickson
et
al
shown
use
multiplex
rtpcr
children
hospitalis
lrti
infect
seven
common
respiratori
virus
similarli
recent
survey
enceph
lead
hospitalis
usa
reveal
nearli
aetiolog
khetsuriani
et
al
absenc
specif
antivir
treatment
virus
limit
prescript
biolog
test
weak
perform
diagnost
test
base
viral
cultur
serolog
major
explan
situat
nat
implement
mani
larg
european
hospit
significantli
improv
viral
diagnosi
howev
sever
obstacl
gener
molecular
diagnost
smaller
decentr
laboratori
major
obstacl
fact
except
hiv
hbv
hcv
cmv
virolog
nat
often
homebrew
assay
sometim
suffer
bad
perform
poor
batch
batch
consist
howev
qualiti
nat
percentag
falseposit
result
reflect
laboratori
crosscontamin
use
high
drop
wallac
et
al
tabl
show
product
current
commercialis
major
compani
virus
hiv
hbv
hcv
although
list
may
exhaust
asr
ruo
kit
although
ec
mark
major
reagent
design
run
realtim
platform
result
shown
liolio
et
al
illustr
interest
multiplex
detect
respiratori
virus
nat
one
hundr
fortythre
clinic
specimen
test
use
hexaplex
assay
prodess
inc
usa
detect
six
virus
singl
tube
use
pcr
detect
micropl
captur
peroxidaselabel
probe
sampl
detect
prodess
assay
immunofluoresc
viral
cultur
tabl
tabl
multiplex
nat
detect
respiratori
virus
hexaplex
prodess
inc
dnamicroarray
dnachip
power
detect
tool
combin
amplif
techniqu
detect
virus
viru
variant
review
clewley
wang
et
al
describ
microarray
spot
oligonucleotid
repres
five
conserv
sequenc
base
conserv
among
repres
sequenc
viru
sequenc
align
viru
interest
chip
contain
differ
probe
follow
pcr
amplif
genet
materi
clinic
specimen
use
random
primer
hybridis
onto
microarray
abl
identifi
respiratori
virus
enteroviru
rhinoviru
paramyxoviru
adenoviru
herpesviru
famili
howev
techniqu
yet
extens
valid
routin
diagnosi
clinic
virolog
laboratori
develop
assay
combin
rtpcr
dnamicroarray
detect
virus
array
manufactur
use
photolithographi
situ
synthesi
technolog
affymetrix
usa
contain
oligonucleotid
sequenc
signatur
identifi
use
extens
sequenc
databas
conserv
virus
genu
famili
subtyp
isol
viru
found
virus
base
signatur
probe
perfectli
match
target
probe
mismatch
interrog
posit
present
array
polymorph
present
near
signatur
variant
probe
may
also
present
consensu
primer
design
enteroviru
flaviviru
herpesvirida
parainfluenza
influenza
viru
rsv
adenoviru
combin
multiplex
detect
pcr
rtpcr
assay
diagnosi
viral
respiratori
cn
infect
follow
amplif
dna
label
use
newli
develop
diazomethyl
chemistri
laayoun
et
al
complet
line
instrument
sampl
prepar
thermocycl
hybridis
station
laser
scanner
avail
perform
assay
describ
respiratori
assay
design
detect
six
major
virus
parainfluenza
rsv
ab
influenza
b
singl
specimen
demonstr
high
clinic
sensit
preliminari
evalu
fig
illustr
discriminatori
capac
technolog
cn
virus
assay
identif
human
papilloma
viru
hpv
commercialis
sever
compani
detect
highli
pathogen
hpv
type
high
predict
valu
cervic
carcinoma
howev
number
hpv
type
less
close
associ
cervic
cancer
high
dnamicroarray
may
thu
appropri
multiplex
detect
type
assay
describ
distribut
biomedlab
co
southkorea
base
consensu
amplif
probe
abl
detect
discrimin
hpv
type
shown
associ
hpv
posit
lesion
differ
sever
carcinoma
wherea
hpv
infect
found
case
cytolog
normal
viral
load
platform
avail
sever
ivd
compani
versant
bayer
diagnost
coba
ampliprep
amplicor
roch
diagnost
minimagnuclisen
easyq
biomerieux
signific
progress
made
abil
hiv
assay
detect
subtyp
commerci
assay
exist
analyt
sensit
hbv
viral
load
assay
increas
reach
perform
hiv
assay
especi
case
infect
variant
low
replic
compet
effici
treatment
monitor
immunosuppress
patient
exampl
case
organ
transplant
viral
load
assay
also
develop
epsteinbarr
viru
varicellazoost
viru
genotyp
test
commerci
avail
part
biolog
followup
treat
patient
although
homebrew
assay
still
use
laboratori
korn
et
al
hiv
hbv
resist
assay
well
hcv
subtyp
assay
gener
base
sequenc
technolog
trugen
hiv
hbv
bayer
healthcar
viroseq
celera
diagnost
genotyp
hcv
kit
bayer
healthcar
hybridis
techniqu
lipa
assay
innogenet
belgium
also
use
howev
number
probe
spot
nitrocellulos
strip
limit
polymorph
detect
conveni
hcv
subtyp
resist
test
base
detect
high
number
mutat
addit
hiv
hbv
highli
variabl
genom
natur
occur
polymorph
present
vicin
resist
mutat
may
affect
bind
effici
probe
dnamicroarray
altern
resist
type
reagent
virus
bacteria
develop
assay
base
rtpcr
detect
fig
biomerieux
dnamicroarray
detect
neurotrop
virus
follow
nucleic
acid
purif
amplif
perform
pcr
use
singl
touchdown
protocol
three
tube
one
herpesvirida
one
primer
pair
hhv
one
enterovirus
one
primer
pair
serotyp
one
flavivirus
one
primer
pair
virus
amplif
product
combin
label
use
diazomethyl
chemistri
hybridis
dnamicroaaray
contain
oligonucleotid
two
four
probe
use
detect
base
sequenc
signatur
determin
viru
total
probe
synthesis
dnamicroarray
design
simultan
detect
virus
herpesvirida
famili
flaviviru
enteroviru
paramyxoviru
poliomaviru
bunyaviru
orthopoxviru
genu
amplicon
gener
resolv
use
bioanalyz
agil
technolog
b
imag
dnamicroarray
obtain
confoc
laser
reader
c
resolut
capabl
array
close
relat
virus
hybridis
differ
effici
heterolog
probe
high
densiti
probe
array
design
detect
antiretrovir
resist
mutat
simultan
gag
cleavag
site
proteas
revers
transcriptas
integras
assay
test
panel
patient
total
relev
codon
comparison
classic
sequencebas
method
key
resist
mutat
correctli
identifi
codon
proteas
revers
transcriptas
respect
gonzalez
et
al
also
develop
similar
assay
detect
polymorph
complet
hbv
genom
antivir
resist
mutat
pol
gene
vaccin
diagnost
immunotherapi
mutat
gene
mutat
basic
core
promot
precor
core
x
region
may
impact
diseas
evolut
treatment
effici
assay
current
evalu
frame
hepbvar
european
collabor
group
studi
emerg
variant
hepat
b
viru
come
year
laboratori
offer
clinician
viral
diagnosi
base
nucleic
acid
test
mani
biolog
instrument
problem
slow
gener
molecular
assay
resolv
sever
other
remain
need
address
major
improv
expect
integr
autom
nat
diagnost
platform
reduc
handsontim
timetoresult
cost
increas
throughput
ivd
compani
engag
develop
program
provid
clinic
virologist
equip
applic
menu
adapt
diagnosi
need
